Peter Lawson, D.Phil. Peter Lawson, D.Phil. Barclays Iovance Biotherapeutics to Present at Upcoming Conferences Read more about Iovance Biotherapeutics to Present at Upcoming Conferences Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update Read more about Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Tuesday, February 25, 2020 Read more about Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Tuesday, February 25, 2020 Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences Read more about Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences Reni Benjamin, Ph.D. Reni Benjamin, Ph.D. JMP Securities LLC Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel Read more about Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog Read more about Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement Read more about Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement Iovance Biotherapeutics to Present at Upcoming Investor Conferences in December Read more about Iovance Biotherapeutics to Present at Upcoming Investor Conferences in December Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last » Subscribe to
Iovance Biotherapeutics to Present at Upcoming Conferences Read more about Iovance Biotherapeutics to Present at Upcoming Conferences
Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update Read more about Iovance Biotherapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Tuesday, February 25, 2020 Read more about Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call and Webcast on Tuesday, February 25, 2020
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences Read more about Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel Read more about Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel
Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog Read more about Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog
Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement Read more about Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement
Iovance Biotherapeutics to Present at Upcoming Investor Conferences in December Read more about Iovance Biotherapeutics to Present at Upcoming Investor Conferences in December
